Show simple item record

AuthorShurrab, Farah M
AuthorYounes, Nadin
AuthorAl-Sadeq, Duaa W
AuthorLiu, Na
AuthorQotba, Hamda
AuthorAbu-Raddad, Laith J
AuthorNasrallah, Gheyath K
Available date2022-03-07T09:21:19Z
Publication Date2022-02-26
Publication NameInternational Journal of Infectious Diseases
Identifierhttp://dx.doi.org/10.1016/j.ijid.2022.02.052
CitationFarah M. Shurrab , Nadin Younes , Duaa W. Al-Sadeq , Na Liu , Hamda Qotba , Laith J. Abu-Raddad , Gheyath K. Nasrallah , Performance evaluation of novel fluorescent-based lateral immune flow assay (LIFA) for rapid detection and quantification of total anti SARS-CoV-2 S-RBD binding antibodies in infected individuals, International Journal of Infectious Dis eases (2022), doi: https://doi.org/10.1016/j.ijid.2022.02.052
URIhttp://hdl.handle.net/10576/27723
AbstractThe vast majority of the commercially available LFIA is used to detect SARS-CoV-2 antibodies qualitatively. Recently, a novel fluorescence-based LIFA test was developed for quantitative measurement of the total binding antibody units (BAU/mL) against the receptor-binding domain of the SARS-CoV-2 spike protein (S-RBD). To evaluate the performance of the fluorescence LIFA Finecare 2019-nCoV S-RBD test along with its reader (Model No.: FS-113). Plasma from 150 RT-PCR confirmed-positive individuals and 100 pre-pandemic samples were tested by FinCare to access sensitivity and specificity. For qualitative and quantitative validation of the FinCar measurements, the BAU/mL results of FinCare were compared with results of two reference assays: the surrogate virus-neutralizing test (sVNT, GenScript, USA), and the VIDAS®3 automated assay (BioMérieux, France). Finecare showed 92% sensitivity and 100% specificity compared to PCR. Cohen's Kappa statistic denoted moderate and excellent agreement with sVNT and VIDAS®3, ranging from 0.557 (95% CI: 0.32-0.78) to 0.731 (95% CI: 0.51-0.95), respectively. A strong correlation was observed between Finecare/sVNT (r=0.7, p<0.0001) and Finecare/VIDAS®3 (r=0.8, p<0.0001). Finecare is a reliable assay and can be used as a surrogate to assess binding and neutralizing antibody response post-infection or vaccination, particularly in none or small laboratory settings.
Languageen
PublisherElsevier
SubjectCOVID-19
Fluorescence immunoassay
Lateral Flow Assay
SARS-CoV-2
Serology
TitlePerformance evaluation of novel fluorescent-based lateral flow immunoassay (LFIA) for rapid detection and quantification of total anti-SARS-CoV-2 S-RBD binding antibodies in infected individuals
TypeArticle
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record